Monitoring immunoglobulin heavy chain and T‑cell receptor gene rearrangement in cfDNA as minimal residual disease detection for patients with acute myeloid leukemia

Zhong, Ling; Chen, Jiao; Huang, Xiaobing; Li, Yanxing; Jiang, Tao

doi:10.3892/ol.2018.8966

Cited by 14 publications

(13 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…High expression of EMTrelated gene vimentin is signi cantly associated with poor prognosis of AML [52]. Zhong et al showed that TCR gene rearrangement can be used to monitor minimal residual disease in AML patients [53]. Previous studies showed that WT1-speci c T cell receptor can be used for the treatment of AML, and can prevent the recurrence of AML after hematopoietic cell transplantation [54,55].…”

Section: Discussionmentioning

confidence: 99%

Identification of a novel small nucleolar RNAs prognostic signature for patients with acute myelocytic leukemia

Huang¹,

Liao²,

Li³

2020

Preprint

View full text Add to dashboard Cite

Background: This study mainly used The Cancer Genome Atlas (TCGA) RNA sequencing dataset to screen prognostic snoRNAs of acute myeloid leukemia (AML), and used for the construction of prognostic snoRNAs signature for AML. Methods: A total of 130 AML patients with RNA sequencing dataset were used for prognostic snoRNAs screenning. SnoRNAs co-expressed genes and differentially expressed genes (DEGs) were used for functional annotation, as well as gene set enrichment analysis (GSEA). Connectivity Map (CMap) also used for potential targeted drugs screening. Results:Through genome-wide screening, we identified 30 snoRNAs that were significantly associated with the prognosis of AML. Then we used the step function to screen a prognostic signature composed of 14 snoRNAs (SNORD72, SNORD38, U3, SNORA73B, SNORD79, SNORA73, SNORD12B, SNORA74, SNORD116-12, SNORA65, SNORA14, snoU13, SNORA75, SNORA31), which can significantly divide AML patients into high- and low-risk groups. Through GSEA, snoRNAs co-expressed genes and DEGs functional enrichment analysis, we screened a large number of potential functional mechanisms of this prognostic signature in AML, such as phosphatidylinositol 3-kinase-Akt ,Wnt, epithelial to mesenchymal transition, T cell receptors, NF-kappa B, mTOR and other classic cancer-related signaling pathways. In the subsequent targeted drug screening using CMap, we also identified six drugs that can be used for AML targeted therapy, they were alimemazine, MG-262, fluoxetine, quipazine, naltrexone and oxybenzone. Conclusion: Our current study was constructed an AML prognostic signature based on the 14 prognostic snoRNAs, which may serve as a novel prognostic biomarker for AML.

show abstract

Section: Discussionmentioning

confidence: 99%

Identification of a novel small nucleolar RNAs prognostic signature for patients with acute myelocytic leukemia

Huang¹,

Liao²,

Li³

2020

Preprint

View full text Add to dashboard Cite

show abstract

“…A resent research suggests that patients with autosomal recessive agammaglobulinemic have IGHM gene mutations [17]. Also, the mu-chain of immunoglobulin gene rearrangement was detected in myeloid leukemia cells from AML patients, and the survival rate of AML patients was signi cantly lower [13,14,16,18,19]. Neeraj et al also found that gene rearrangement of IGHM in the diffuse large B cell lymphoma (DLBCL) [20].…”

Section: Discussionmentioning

confidence: 99%

Analysis of the Differential Expression and Prognostic Relationship of DEGs in AML based on TCGA Database

Zhang

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Acute myeloid leukemia (AML) is a common and lethal hematological malignant hyperplastic disease originating from hematopoietic stem cells. The purpose of this study is to obtain the key AML survival-related differentially expressed gene. Methods: RNA sequencing (RNA-Seq) data and clinical information of patients were downloaded from the TCGA-LAML database. We focused the intersectional genes of survival-related DEGs, cytogenetics risk related-DEGs, and the top 10 pathways of both up- and down-regulated of Normalization Enrichment Score (NES). Multivariate Cox regression analyses were performed to analyze the independent factors for AML. The Kaplan–Meier and Nomogram analyses were plotted to predict and compare survival of AML patients. The validation of DEGs were performed by a clinical follow-up investigation.Results: 151 RNA-Seq samples for 60,488 genes and 200 clinical samples were selected from the TCGA-database. After filtering with the conditions about survival-related DEGs, cytogenetics-risk associated, and predicted in top 10 pathways, IGHM was the only remaining gene. Cox analysis showed that IGHM expression and age displayed were intendent factors to the patients’ survival (P<0.05). Higher IGHM expression was identified in poor survival group (P<0.05), with 68%, 43%, and 30% in 1, 3, and 5-year survival investigation. GSEA analysis revealed that IGHM were mainly enriched in the immune response. In Chinese population, IGHM displayed its significance not in the childhood AML patients but in adult ones. Conclusion: High expression of IHGM gene is an independent risky factor for the survival of patients with AML, which can be an important molecular marker for AML prognosis.

show abstract

“…In 2020, Nicholas et al performed targeted NGS of ctDNA and BM DNA in patients with AML and suggested that they may be complementary to the assessment and monitoring of patients [ 88 ]. Zhong et al detected monoclonal immunoglobulin gene rearrangement in AML ctDNA, which is expected to be applied in MRD monitoring [ 89 ]. The detection of IgH and TCR rearrangement is common in lymphoid malignancy but rare in AML.…”

Section: Utility Of Ctdna Characterization In Hematopoietic Tumorsmentioning

confidence: 99%

Role of Circulating Tumor DNA in Hematological Malignancy

Ogawa

Yokoyama

Imoto

et al. 2021

Cancers

View full text Add to dashboard Cite

With the recent advances in noninvasive approaches for cancer diagnosis and surveillance, the term “liquid biopsy” has become more familiar to clinicians, including hematologists. Liquid biopsy provides a variety of clinically useful genetic data. In this era of personalized medicine, genetic information is critical to early diagnosis, aiding risk stratification, directing therapeutic options, and monitoring disease relapse. The validity of circulating tumor DNA (ctDNA)-mediated liquid biopsies has received increasing attention. This review summarizes the current knowledge of liquid biopsy ctDNA in hematological malignancies, focusing on the feasibility, limitations, and key areas of clinical application. We also highlight recent advances in the minimal residual disease monitoring of leukemia using ctDNA. This article will be useful to those involved in the clinical practice of hematopoietic oncology.

show abstract

Monitoring immunoglobulin heavy chain and T‑cell receptor gene rearrangement in cfDNA as minimal residual disease detection for patients with acute myeloid leukemia

Cited by 14 publications

References 25 publications

Identification of a novel small nucleolar RNAs prognostic signature for patients with acute myelocytic leukemia

Identification of a novel small nucleolar RNAs prognostic signature for patients with acute myelocytic leukemia

Analysis of the Differential Expression and Prognostic Relationship of DEGs in AML based on TCGA Database

Role of Circulating Tumor DNA in Hematological Malignancy

Contact Info

Product

Resources

About